← All trials
NCT05056220
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Sep 30, 2024
- Completion date
- Oct 31, 2024
- First posted
- Sep 24, 2021
- Last posted
- Sep 24, 2021
- Enrollment
- 240
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Odense University HospitalLead sponsor
- University of Southern DenmarkSponsor investigator
- University of Southern DenmarkOverall official - principal investigator
- EASL - CLIF ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.